RESUMO
BACKGROUND: Vinblastine (VBL) is a cytostatic drug frequently applied in children with lymphoma and progressive low-grade glioma (LGG), with hematotoxicity as the main side effect. CASE REPORT: Here, the case of a 7-month-old girl with tumor progression of an LGG during standard chemotherapy with carboplatin and vincristine, is presented. Switching to VBL led to a 20-30- fold increase of transaminases (grade IV CTCAE 5.0), spontaneously resolving after the end of treatment. The toxicity is possibly age-related since it did not re-occur at the restart of VBL at 4 years old. This finding might have consequences for toxicity screening in future protocols, especially when including infants.
Assuntos
Antineoplásicos Fitogênicos/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Vimblastina/efeitos adversos , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/patologia , Carboplatina/administração & dosagem , Feminino , Glioma/tratamento farmacológico , Glioma/patologia , Humanos , Lactente , Neoplasias do Nervo Óptico/tratamento farmacológico , Neoplasias do Nervo Óptico/patologia , Vimblastina/administração & dosagem , Vincristina/administração & dosagemRESUMO
BACKGROUND: A drug interaction between capecitabine and coumarin may result in an increased INR and bleeding complications. CASE DESCRIPTION: We describe an 80-year-old woman who presented with rectal bleeding and an increased INR due to the concomitant use of acenocoumarol and capecitabine for atrial fibrillation and metastatic cecal cancer, respectively. CONCLUSION: In patients with a compelling indication for treatment with capecitabine and anticoagulant therapy, conversion to low-molecular weight heparin should be considered.
Assuntos
Acenocumarol/efeitos adversos , Anticoagulantes/efeitos adversos , Antimetabólitos Antineoplásicos/efeitos adversos , Desoxicitidina/análogos & derivados , Fluoruracila/análogos & derivados , Hemorragia Gastrointestinal/induzido quimicamente , Acenocumarol/uso terapêutico , Idoso de 80 Anos ou mais , Anticoagulantes/uso terapêutico , Antimetabólitos Antineoplásicos/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Capecitabina , Desoxicitidina/efeitos adversos , Desoxicitidina/uso terapêutico , Interações Medicamentosas , Transfusão de Eritrócitos , Feminino , Fluoruracila/efeitos adversos , Fluoruracila/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Coeficiente Internacional Normatizado , Neoplasias Retais/tratamento farmacológicoRESUMO
OBJECTIVE OF THE STUDY: To identify the prevalence of potential drug-drug interactions between hospital pharmacy dispensed anti-cancer agents and community pharmacy dispensed drugs. SETTING: A retrospective cohort study was conducted on the haematology/oncology department of the internal medicine ward in a large teaching hospital in Amsterdam, the Netherlands. METHOD: Prescription data from the last 100 patients treated with anti-cancer agents were obtained from Paracelsus, the chemotherapy prescribing system in the hospital. The community pharmacy dispensed drugs of these patients were obtained by using OZIS, a system that allows regionally linked pharmacies to call up active medication on any patient. Both medication lists were manually screened for potential drug-drug interactions by using several information sources on interactions, e.g. Pubmed, the Flockhart P450 table, Micromedex and Dutch reference books. MAIN OUTCOME MEASURE: Prevalence of potential drug-drug interactions between anti-cancer agents provided by the hospital pharmacy and drugs dispensed by the community pharmacy. RESULTS: Ninety-one patients were included in the study. A total of 31 potential drug-drug interactions were found in 16 patients, of which 15 interactions were clinically relevant and would have required an intervention. Of these interactions 1 had a level of severity ≥ D, meaning the potential drug-drug interaction could lead to long lasting or permanent damage, or even death. The majority of the interactions requiring an intervention (67%) had a considerable level of evidence (≥ 2) and were based on well-documented case reports or controlled interaction studies. Most of the potential drug-drug interactions involved the antiretroviral drugs (40%), proton pump inhibitors (20%) and antibiotics (20%). The anti-cancer drug most involved in the drug-drug interactions is methotrexate (33%). CONCLUSION: This study reveals a high prevalence of potential drug-drug interactions between anti-cancer agents provided by the hospital pharmacy and drugs dispensed by the community pharmacy. It shows us there is need for an optimal medication surveillance mechanism to detect potential drug-drug interactions between these two groups of medication, especially because of the high toxicity of anticancer drugs and thus the severe consequences these interactions can have for the patient.